Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Milnacipran and D-cycloserine in PTLS
NCT02687165Terminated
- Sponsor
- New York State Psychiatric Institute
- Start
- Jan 2016
- Primary completion
- Jan 2017
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial in Post-treatment Lyme disease syndrome (PTLDS) comparing Milnacipran + D-cycloserine with Milnacipran + Placebo (2 arms). Primary endpoint: Brief Pain Inventory at 12 weeks. Started Jan 2016; status: terminated.
02
Drugs
d-cycloserine
03
Conditions
Post-treatment Lyme disease syndrome (PTLDS)
Beyond the preview
Go deeper on NCT02687165.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02687165.